Now, it’s worth noting Stock Advisor's total average return is 991% — a market-crushing outperformance compared to 195% for ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike to ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) share more than a few similarities despite being at different stages of the biotech lifecycle. Both companies are betting that ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Editas Medicine announces advancements in in vivo CRISPR gene editing, optimizing costs, and reducing workforce while focusing on hematologic diseases. Editas Medicine, Inc. has announced a strategic ...

From rare diseases to chronic conditions, epigenetic editing unlocks new ways to control gene activity without altering the genetic code.

A cutting-edge base-edited CAR T-cell therapy is opening a revolutionary new frontier for patients battling aggressive T-cell ...